Cytek Biosciences Closes Series D Funding with $120M

Cytek Biosciences announced the closing of a $120 million Series D funding round, co-led by RA Capital and Hillhouse Capital, with OrbiMed and LYFE Capital also participating. The investment will be used to expand Cytek’s global infrastructure and maintain growth. RA Capital and Hillhouse Capital have also joined Cytek’s board of directors.

“Cytek is ushering in flow cytometry’s next chapter with its proven, unique combination of innovative technologies,” said Andrew Levin, managing director of RA Capital. “We are excited to join them on their mission to advance cancer and cell biology research.”